Recently, Viwit Pharmaceuticals received the "Drug registration certificate" issued by China National Medical Products Administration (NMPA) for Bimatoprost Eye Drops. The approval number is H20244103. This signifies that the product has received official approval for the Chinese market and has successfully passed the generic drug consistency evaluation, thereby becoming the second domestic generic drug of its kind.

Bimatoprost Eye Drops are primarily used clinically to lower eye pressure in patients with open-angle glaucoma and high intraocular pressure. Its pharmacological action is as follows: Bimatoprost is a synthetic prostamide, a structural analogue of prostaglandin with a lowering eye pressure active, selectively simulating the action of natural prostamide. Bimatoprost is believed to lower eye pressure by increasing the outflow of aqueous humor through the trabecular meshwork and sclera.

It has also been reported that this product promotes eyelash growth and is used to treat hypotrichosis by increasing the growth of eyelashes (including length, thickness, and density). The changes in eyelashes caused by Bimatoprost eye drops are reversible. In addition, Bimatoprost eye drops 0.03% is the only prescription drug approved by the US FDA for eyelash growth, and the subjects who used the active ingredient of Bimatoprost 0.03% eye drops for 16 consecutive weeks showed significant increases in eyelash length and density, making the product highly acclaimed in the medical aesthetic market!

High intraocular pressure is the main factor leading to glaucomatous visual field defects, and glaucoma is a sight-threatening, blindness-causing eye disease, second only to cataracts. Clinically, the most commonly used drugs to lower eye pressure include cholinergic agents, cholinesterase inhibitors, carbonic anhydrase inhibitors, beta-adrenergic receptor blockers. And prostaglandins are new drugs that have been studied and proven effective for lowering eye pressure in recent years.

A meta-analysis of the effectiveness and safety of Bimatoprost，latanoprost, and other prostaglandin structural analogs in the treatment of glaucoma shows that Bimatoprost eye drops are an ideal first-line glaucoma drug:

1 | have good effects on lowering eye pressure, maintaining stable eye pressure, and reducing fluctuations in eye pressure;

2 | have good synergistic effects with other drugs;

3 | have fewer local and systemic adverse reactions;

4 | have high compliance, allowing patients to continue using it in stages;

5 | from the perspective of cost-effectiveness, it has good cost-effectiveness.